Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
52.13
+0.09 (0.16%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Travere Therapeutics Employees
Travere Therapeutics had 497 employees as of December 31, 2025. The number of employees increased by 112 or 29.09% compared to the previous year. That makes Travere Therapeutics the 20,148th largest employer in the world and 2,692nd in the United States.
Employees
497
Change (1Y)
112
Growth (1Y)
29.09%
Revenue / Employee
$1,189,799
Profits / Employee
-$87,453
Market Cap
4.91B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 497 | 112 | 29.09% |
| Dec 31, 2024 | 385 | 5 | 1.32% |
| Dec 31, 2023 | 380 | -82 | -17.75% |
| Dec 31, 2022 | 462 | 152 | 49.03% |
| Dec 31, 2021 | 310 | 48 | 18.32% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Mirum Pharmaceuticals | 433 |
| CRISPR Therapeutics AG | 393 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
| Definium Therapeutics | 106 |
| Erasca | 103 |
TVTX News
- 8 days ago - Travere Therapeutics announces FILSPARI data presentations at ASN Kidney Week - TheFly
- 8 days ago - Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026 - Business Wire
- 16 days ago - Travere Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts
- 17 days ago - Travere Therapeutics price target raised to $89 from $75 at Guggenheim - TheFly
- 18 days ago - Travere Therapeutics receives notice of allowance for FILSPARI patent - TheFly
- 18 days ago - Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis - Business Wire
- 19 days ago - Travere Therapeutics CEO Dube to step down - TheFly
- 19 days ago - Travere Therapeutics Announces Planned Chief Executive Officer Transition - Business Wire